Down, down, down it goes ... where it will stop, nobody knows ...
The potential market share for Myloral could be huge if the trials are successful. My opinion is that it will take a couple of years *after* the release of Myloral for things to pick up if it is approved. That is because right now, very little is known regarding the mechanisms of oral tolerance. My friend Miyachi who is an immunologist at the U. Tokyo Medical School tells me that in some preparations antigen feeding actually exacerbates the problems. But clearly positive results have been recorded as well. My feeling is that a synergy will be found that will make Myloral a very effective therapy for MS. Perhaps with interferon gamma, cytokines, interleukins, etc. But alone, Myloral seems work spotty at best, if I take the now infamous conversation I had at face value. When the stock goes down below 8, I am going long for the future. But for now, I will make a few $$$ on the short side. GROWL!
- Organ |
